🇺🇸 naratriptan HCl in United States
51 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 51
Most-reported reactions
- Nausea — 8 reports (15.69%)
- Headache — 7 reports (13.73%)
- Condition Aggravated — 5 reports (9.8%)
- Drug Ineffective — 5 reports (9.8%)
- Malaise — 5 reports (9.8%)
- Migraine — 5 reports (9.8%)
- Feeling Abnormal — 4 reports (7.84%)
- Hot Flush — 4 reports (7.84%)
- Hyperhidrosis — 4 reports (7.84%)
- Sleep Apnoea Syndrome — 4 reports (7.84%)
Other Neurology approved in United States
Frequently asked questions
Is naratriptan HCl approved in United States?
naratriptan HCl does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for naratriptan HCl in United States?
Cady, Roger, M.D. is the originator. The local marketing authorisation holder may differ — check the official source linked above.